Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Llueca, Antoni; Herraiz Roda, José Luis; Català Masó, Carmen; Serra Rubert, Anna; Rivadulla, Isabel; Escrig-Sos, Javier
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General HospitalAutoría
Fecha de publicación
2016Editor
Elmer PressCita bibliográfica
LLUECA ABELLA, José Antonio; HERRÁIZ RODA, José Luis; CATALÀ MASÓ, Carmen; SERRA, Anna; RIVADULLA, Isabel; ESCRIG SOS, Javier. Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital. Journal of Clinical Gynecology and Obstetrics (2015), v 4, n. 3, pp. 251-257Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
http://www.jcgo.org/index.php/jcgo/article/view/345Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background: The aim of the study was to evaluate the initial efficiency
and security of maximal effort cytoreductive surgery in stages
III and IV of ovarian cancer at a university hospital.
Methods: Thirty-four ... [+]
Background: The aim of the study was to evaluate the initial efficiency
and security of maximal effort cytoreductive surgery in stages
III and IV of ovarian cancer at a university hospital.
Methods: Thirty-four patients with stage III and IV ovarian carcinoma
underwent surgery between January 2013 and June 2014 in
the University General Hospital of Castellon (Spain). Patients with
primary and relapse ovarian cancer were included. The extent of disease,
type of surgical technique, amount of tumor prior to surgery and
amount of residual disease after surgery were recorded. To quantify
the efficiency and the security of the procedure, the complete cytoreduction
and the morbidity and the mortality rates were described.
Results: Of the patients 26.4% received neoadjuvant chemotherapy.
Complete cytoreductive surgery, without evident residual tumor at the
end of the procedure, was obtained in 79% of patients and optimal cytoreductive
surgery (CC0-CC1) in 91%. Surgical complications were
found in 56% of patients and two deaths (6%) occurred attributable to
surgery. The disease free interval was 15 months.
Conclusions: This study confirms that with experienced multidisciplinary
teams and in tertiary referral hospitals, 79% of complete
cytoreduction surgery in advanced ovarian cancer can be achieved
but they must be prepared to deal with a high rate of complications [-]
Publicado en
Journal of Clinical Gynecology and Obstetrics (2015), v 4, n. 3Derechos de acceso
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [637]